PHAR: קונצנזוס שווי הוגן Pharming Group NV

Pharming Group N.V. (PHAR) profitability relies on the commercialization of Ruconest and Joenja, where prescription volume and insurance reimbursements serve as key factors, and the metric stands at 29.84. The business model is easily scalable: low costs for producing finished formulas ensure high profits during expansion. This price chart, serving as a valuation tool, demonstrates market expectations for the asset. The drug for angioedema guarantees a stable cash flow.

This indicator represents the weighted average share price calculated based on target prices from leading investment banks. The increase in the median analyst target price confirms market confidence in the efficiency of cold chain logistics and the preservation of Pharming Group N.V. (PHAR) biologics. The trend of this curve reflects expectations for business margins while minimizing warehousing risks. Investors should view this metric as a barometer of fundamental attractiveness. A stable consensus signals the long-term sustainability of the company's capitalization.